Holen Sie sich die Stockscreener-App
1.155
1.69%
-0.025
Handel nachbörslich:
1.18
0.025
+2.16%
Schlusskurs vom Vortag:
$1.18
Offen:
$1.18
24-Stunden-Volumen:
78,278
Relative Volume:
0.47
Marktkapitalisierung:
$36.24M
Einnahmen:
$90,000
Nettoeinkommen (Verlust:
$-33.89M
KGV:
-1.0632
EPS:
-1.0863
Netto-Cashflow:
$-24.68M
1W Leistung:
+0.87%
1M Leistung:
-9.38%
6M Leistung:
-20.00%
1J Leistung:
-29.27%
1-Tages-Spanne:
$1.15
$1.18
1-Wochen-Bereich:
$1.15
$1.20
52-Wochen-Spanne:
$0.952
$1.9454
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Firmenname
Actinium Pharmaceuticals Inc
Sektor
Branche
Telefon
646-767-3870
Adresse
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.155 | 37.02M | 90,000 | -33.89M | -24.68M | -1.0863 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-07 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-02-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-08-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-11-05 | Eingeleitet | Alliance Global Partners | Buy |
| 2017-12-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-14 | Eingeleitet | Maxim Group | Buy |
| 2016-08-25 | Eingeleitet | ROTH Capital | Buy |
| 2016-02-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2014-10-01 | Eingeleitet | MLV & Co | Buy |
| 2014-07-22 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Actinium Pharmaceuticals Inc Aktie (ATNM) Neueste Nachrichten
ATNM Should I Buy - Intellectia AI
Actinium (ATNM) Delivers Q1 2026 Beat — EPS $-0.18 vs $-0.24 ExpectedMost Discussed Stocks - Newser
Actinium (ATNM) Falls -2.34% — Watching $1.19 Support 2026-05-15Viral Trade Signals - newser.com
ATNM Stock Price, Quote & Chart | ACTINIUM PHARMACEUTICALS INC (NYSEARCA:ATNM) - ChartMill
TradingKey - TradingKey
MSN Money - MSN
Actinium: Q1 Earnings Snapshot - kare11.com
[10-Q] Actinium Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan
Actinium Pharmaceuticals Inc. (ATNM) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization - Barchart.com
Actinium presents preclinical data on AML drug at AACR meeting By Investing.com - Investing.com India
Actinium Pharmaceuticals (ATNM) Unveils Promising Preclinical Fi - GuruFocus
Actinium Pharmaceuticals (ATNM) Presents Promising Data on Actim - GuruFocus
Actinium presents preclinical data on AML drug at AACR meeting - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 - Investing.com
Actinium Pharmaceuticals presents preclinical data for ATNM-400 By Investing.com - Investing.com South Africa
Dr. Electric Explains What Colorado Springs Homeowners Should Check Before Summer Electrical Demand Peaks - Weekly Voice
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting - PR Newswire
SDEV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting - PR Newswire
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
Actinium (ATNM) Stock: Is It a Strong Buy? (+4.00%) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
ATNM Actinium Pharmaceuticals Inc. (Delaware) gains four percent after Q4 2025 results despite slight EPS miss against analyst expectations.Consensus Forecast - Newser
What are analysts saying about Actinium (ATNM) Stock | Price at $1.07, Down 0.93%Expert Stock Picks - newser.com
Aug Macro: Is now the right time to enter Actinium Pharmaceuticals Inc2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Actinium Pharma unveils groundbreaking data on radiotherapy platform at AACR 2026 - Indian Pharma Post
Aug Highlights: Can Actinium Pharmaceuticals Inc outperform in the next rallyJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Support Test: Is Actinium Pharmaceuticals Inc subject to activist investor interest2026 Weekly Recap & Target Return Focused Picks - baoquankhu1.vn
ATNM Q4 2025 Earnings: Actinium Pharma misses EPS, reports zero revenueForward Guidance Trends - Newser
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - The AI Journal
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting – Company AnnouncementFT.com - Financial Times
Aug Mood: Can Actinium Pharmaceuticals Inc outperform in the next rallyWeekly Market Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
What is HC Wainwright’s Estimate for ATNM FY2026 Earnings? - Defense World
ATNM Shareholders Have Opportunity to Lead Actinium Pharmaceutica - The National Law Review
Research Analysts Set Expectations for ATNM Q1 Earnings - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Receives “Overweight” Rating from Stephens - Defense World
ATNM: Stephens & Co. Reiterates Overweight Rating with $5.00 Tar - GuruFocus
Actinium Pharmaceuticals 2026 Annual Report: Clinical-Stage Radiopharmaceutical Innovations, Competitive Strengths, and Regulatory Risk Factors - Minichart
Actinium: Q4 Earnings Snapshot - KVUE
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Actinium Pharmaceuticals (NYSE: ATNM) outlines radiotherapy pipeline, losses and 2026 manufacturing plans - Stock Titan
Actinium Pharmaceuticals (ATNM) Eps Diluted (TTM) - Zacks Investment Research
Portfolio Shifts: What is the dividend yield of Actinium Pharmaceuticals Inc2026 Market Overview & Weekly High Return Stock Forecasts - baoquankhu1.vn
Actinium Pharmaceuticals (ATNM) board adopts annual Say-on-Pay advisory votes - Stock Titan
Comparing UCB (OTCMKTS:UCBJF) and Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Fundamentals Check: Is Actinium Pharmaceuticals Inc undervalued by DCF analysis - baoquankhu1.vn
If You Invested $1,000 in Actinium Pharmac (ATNM) - Stock Titan
Stop Loss: What is the next catalyst for Actinium Pharmaceuticals IncCEO Change & Reliable Breakout Forecasts - baoquankhu1.vn
Alpha Emitter Market Size, Share & Growth Graph by 2034 - Straits Research
Analysis Recap: Is Actinium Pharmaceuticals Inc stock good for income investors2026 Market Mood & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Wall Street Recap: Is Actinium Pharmaceuticals Inc stock trending bullishInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Finanzdaten der Actinium Pharmaceuticals Inc-Aktie (ATNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):